Alector’s GSK-partnered Alzheimer’s drug flunks Phase 3, plots to halve workforce

Alector said one antibody from its $700 million upfront deal with GSK missed a key endpoint in a Phase 3 study in Alzheimer’s disease. The biotech will end work on that asset ...